Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

PAVmed (PAVM) Cost of Revenue (2021 - 2025)

PAVmed (PAVM) has 5 years of Cost of Revenue data on record, last reported at $55000.0 in Q3 2025.

  • For Q3 2025, Cost of Revenue changed N/A year-over-year to $55000.0; the TTM value through Sep 2025 reached -$6.5 million, changed N/A, while the annual FY2024 figure was $4.8 million, 72.47% down from the prior year.
  • Cost of Revenue reached $55000.0 in Q3 2025 per PAVM's latest filing, up from -$169000.0 in the prior quarter.
  • Across five years, Cost of Revenue topped out at $8.8 million in Q4 2021 and bottomed at -$9.9 million in Q4 2022.
  • Average Cost of Revenue over 5 years is $1.3 million, with a median of $1.6 million recorded in 2022.
  • Peak YoY movement for Cost of Revenue: skyrocketed 1130.08% in 2023, then crashed 241.41% in 2024.
  • A 5-year view of Cost of Revenue shows it stood at $8.8 million in 2021, then tumbled by 213.64% to -$9.9 million in 2022, then soared by 147.16% to $4.7 million in 2023, then plummeted by 241.41% to -$6.6 million in 2024, then skyrocketed by 100.83% to $55000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cost of Revenue were $55000.0 in Q3 2025, -$169000.0 in Q2 2025, and $247000.0 in Q1 2025.